Participant Demographic and Baseline Drinking Factors Can Predict Alcohol Use Disorder Pharmacotherapy Clinical Trial Completion and Drinking Outcomes.

Background: Partially due to the complexity associated with conducting trials, there have been relatively few regulatory agency‐approved medications for the treatment of alcohol use disorder (AUD). Heterogeneity of study samples, such as participant characteristics (including variation in alcohol co...

Full description

Bibliographic Details
Published in:Alcohol, Clinical & Experimental Research Vol. 50; no. 4; pp. 1 - 9
Main Authors: Hoffman, Michaela, Anton, Raymond F., Aldridge, Arnie
Format: research tables/charts Journal Article
Published: Wiley-Blackwell Apr2026
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=193323582&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 193323582
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        29937175
        NACB
      jtl: Alcohol, Clinical & Experimental Research
      issn: 29937175
      maglogo: N
    pubinfo:
      dt: Apr2026
      vid: 50
      iid: 4
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        193323582
        193323582
        193323582
        10.1111/acer.70288
        193323582
      ppf: 1
      ppct: 8
      formats:
      tig:
        atl: Participant Demographic and Baseline Drinking Factors Can Predict Alcohol Use Disorder Pharmacotherapy Clinical Trial Completion and Drinking Outcomes.
      aug:
        au:
          Hoffman, Michaela
          Anton, Raymond F.
          Aldridge, Arnie
        affil: Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston South Carolina,, USA
      sug:
        subj:
          Clinical Trials
          Alcoholism Drug Therapy
          Research Subjects Psychosocial Factors
          Information Needs
          Prediction Models
          Treatment Outcomes
          Human
          North Carolina
          Funding Source
          Male
          Female
          Adult
          Middle Age
          Secondary Analysis
          Descriptive Statistics
          Logistic Regression
          Post Hoc Analysis
          ROC Curve
          Youden's J Statistic
          Chi Square Test
          Analysis of Variance
          T-Tests
          Alcohol Drinking
          Risk Assessment
          Alcohol Abstinence
          World Health Organization Standards
          Age Factors
          Clinical Assessment Tools
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Male
          Female
      ab: Background: Partially due to the complexity associated with conducting trials, there have been relatively few regulatory agency‐approved medications for the treatment of alcohol use disorder (AUD). Heterogeneity of study samples, such as participant characteristics (including variation in alcohol consumption) as well as drinking efficacy endpoints, may lead to inconsistency in results and a potential increase in Type II errors. The aim of this study is to begin to fill in the knowledge gap of optimal clinical trial design by analyzing potential predictors of outcomes. Methods: Five federally funded and publicly available multisite randomized pharmacotherapy clinical trials for the treatment of AUD using similar methodologies to assess drinking outcomes were included. Three FDA‐guided drinking efficacy outcomes were calculated for each study independently and combined: abstinence (no drinking days), no heavy drinking days, WHO 2+ risk drinking level (RDL) reduction as well as a measure of study participant completion. These outcomes were analyzed by logistic regression models including a variety of predictors within the full‐study sample as well as among only participants treated with placebo. Results: The number of days abstinent prior to randomization was a strong positive predictor of all three predefined drinking outcomes. Further analysis indicated a cutoff of less than three to five abstinent days before randomization might be optimal. For the WHO 2+ RDL endpoint, those within the "high" or "very‐high" risk categories were more likely to meet criteria for successful two or more risk level reductions than "medium" risk. Across various demographic variables, only age (older participants) was associated with better outcomes. Conclusions: These findings suggest that some important prestudy drinking characteristics (e.g., less abstinence and older age) as well as being in a higher risk drinking category should be considered for inclusion in future alcohol pharmacotherapy trials.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N